Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125.

BACKGROUND Subjective evaluation of gray-scale and Doppler ultrasound findings (i.e., pattern recognition) by an experienced examiner and preoperative serum levels of CA-125 can both discriminate benign from malignant adnexal (i.e., ovarian, paraovarian, or tubal) masses. We compared the diagnostic performance of these methods in a large multicenter study. METHODS In a prospective multicenter study--the International Ovarian Tumor Analysis--1066 women with a persistent adnexal mass underwent transvaginal gray-scale and color Doppler ultrasound examinations by an experienced examiner within 120 days of surgery. Pattern recognition was used to classify a mass as benign or malignant. Of these women, 809 also had blood collected preoperatively for measurement of serum CA-125. Various levels of CA-125 were used as cutoffs to classify masses. Results from both assays were then compared with histologic findings after surgery. RESULTS Pattern recognition correctly classified 93% (95% confidence interval [CI] = 90.9% to 94.6%) of the tumors as benign or malignant. Serum CA-125 correctly classified at best 83% (95% CI = 80.3% to 85.6%) of the masses. Histologic diagnoses that were most often misclassified by CA-125 were fibroma, endometrioma, and abscess (false-positive results) and borderline tumor (false-negative results). Pattern recognition correctly classified 86% (95% CI = 81.1% to 90.4%) of masses of these four histologic types as being benign or malignant, whereas a serum CA-125 at a cutoff of 30 U/mL correctly classified 41% (95% CI = 34.4% to 47.5%) of them. Pattern recognition assigned a correct specific histologic diagnosis to 333 (59%, 95% CI = 54.5% to 62.8%) of the 567 benign lesions. CONCLUSION Pattern recognition was superior to serum CA-125 for discrimination between benign and malignant adnexal masses.

[1]  F. Jänicke,et al.  [Tumor marker CA 72-4 in ovarian cancer in comparison with CA 125 and D-dimer]. , 1991, Gynäkologisch-Geburtshilfliche Rundschau.

[2]  Y. Kitaoka,et al.  Usefulness and limits of CA-125 in diagnosis of endometriosis without associated ovarian endometriomas. , 2005, Human reproduction.

[3]  H. Hollema,et al.  Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors. , 2000, Gynecologic oncology.

[4]  T. Bourne,et al.  Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) group , 2000, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[5]  R. Newcombe Two-sided confidence intervals for the single proportion: comparison of seven methods. , 1998, Statistics in medicine.

[6]  R G Newcombe,et al.  Improved confidence intervals for the difference between binomial proportions based on paired data. , 1998, Statistics in medicine.

[7]  I. Timor-Tritsch,et al.  Transvaginal ultrasonographic characterization of ovarian masses with an improved, weighted scoring system. , 1994, American journal of obstetrics and gynecology.

[8]  R. Newcombe,et al.  Interval estimation for the difference between independent proportions: comparison of eleven methods. , 1998, Statistics in medicine.

[9]  R. Bast,et al.  The CA 125 tumour-associated antigen: a review of the literature. , 1989, Human reproduction.

[10]  P. Dombernowsky,et al.  Tumor markers in the management of patients with ovarian cancer. , 1995, Cancer treatment reviews.

[11]  Dirk Timmerman,et al.  The use of mathematical models to evaluate pelvic masses; can they beat an expert operator? , 2004, Best practice & research. Clinical obstetrics & gynaecology.

[12]  P. Buamah,et al.  Serum CA 125 concentrations in patients with benign ovarian tumours , 1994, Journal of surgical oncology.

[13]  D. Timmerman,et al.  Subjective assessment of adnexal masses with the use of ultrasonography: an analysis of interobserver variability and experience , 1999, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[14]  T. Bourne,et al.  Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: a multicenter study by the International Ovarian Tumor Analysis Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  N. Vlahos,et al.  Color and Pulsed Doppler Sonography, Gray‐Scale Imaging, and Serum CA 125 in the Assessment of Adnexal Disease , 1996, Obstetrics and gynecology.

[16]  P Maisonneuve,et al.  Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. , 2006, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[17]  T. Bourne,et al.  Transvaginal colour flow imaging: a possible new screening technique for ovarian cancer. , 1989, BMJ.

[18]  I. Vergote,et al.  Evaluation of serum CA 125 level as a tumor marker in borderline tumors of the ovary , 1992, International Journal of Gynecologic Cancer.

[19]  P. Viganò,et al.  Use of the concomitant serum dosage of CA 125, CA 19-9 and interleukin-6 to detect the presence of endometriosis. Results from a series of reproductive age women undergoing laparoscopic surgery for benign gynaecological conditions. , 2004, Human reproduction.

[20]  P. Kenemans,et al.  Heterologous double-determinant immunoradiometric assay CA 125 II: reliable second-generation immunoassay for determining CA 125 in serum. , 1993, Clinical chemistry.

[21]  J. Schlaerth,et al.  Serum CA 125 Levels in Preoperative Evaluation of Pelvic Masses , 1988, Obstetrics and gynecology.

[22]  R. Berkowitz,et al.  Preoperative serum CA-125 levels in borderline tumors of the ovary. , 1992, Gynecologic oncology.

[23]  R. Bast,et al.  Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: Discrimination of benign from malignant disease , 1988, American journal of obstetrics and gynecology.

[24]  T. Bourne,et al.  The characterization of common ovarian cysts in premenopausal women , 2001, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[25]  A. Sood,et al.  Preoperative CA 125 Levels: An Independent Prognostic Factor for Epithelial Ovarian Cancer , 2002, Obstetrics and gynecology.

[26]  B. Davidson,et al.  CA 125 measurement and ultrasonography in borderline tumors of the ovary. , 2000, American journal of obstetrics and gynecology.

[27]  P. Kenemans,et al.  Serum tumor marker immunoassays in gynecologic oncology: establishment of reference values. , 1996, American journal of obstetrics and gynecology.

[28]  R. Bast,et al.  Preoperative Evaluation of Serum CA 125 Levels in Patients With Primary Epithelial Ovarian Cancer , 1986, Obstetrics and gynecology.

[29]  L. Valentin Use of morphology to characterize and manage common adnexal masses. , 2004, Best practice & research. Clinical obstetrics & gynaecology.

[30]  M. Duffy,et al.  CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use , 2004, International Journal of Gynecologic Cancer.

[31]  A. Gadducci,et al.  Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses. , 1996, Gynecologic oncology.

[32]  F. Kikkawa,et al.  Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor. , 1996, Gynecologic oncology.

[33]  M. Kucok Elevated Serum CA-125 concentration in a patient with tuberculous peritonitis mimicking ovarian cancer. , 1998, The Journal of reproductive medicine.

[34]  D. Oram,et al.  A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer , 1991, British journal of obstetrics and gynaecology.

[35]  V. Phupong,et al.  High level of CA 125 due to large endometrioma. , 2004, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[36]  Tumor marker trends in asymptomatic women at risk for ovarian cancer: relevance for ovarian cancer screening. , 1995, Gynecologic oncology.

[37]  Sabine Van Huffel,et al.  Inclusion of CA-125 does not improve mathematical models developed to distinguish between benign and malignant adnexal tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  I. Jacobs,et al.  Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study , 1996, BMJ.

[39]  A. Proietto,et al.  Prognostic importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  P. Kenemans,et al.  Comparison of seven immunoassays for the quantification of CA 125 antigen in serum. , 1998, Clinical chemistry.

[41]  Seth Granberg,et al.  Macroscopic characterization of ovarian tumors and the relation to the histological diagnosis: Criteria to be used for ultrasound evaluation , 1990 .

[42]  F. Jansen,et al.  Sonographic assessment of non-malignant ovarian cysts: does sonohistology exist? , 2004, Human reproduction.

[43]  R. Newcombe,et al.  Confidence intervals for an effect size measure based on the Mann–Whitney statistic. Part 2: asymptotic methods and evaluation , 2006, Statistics in medicine.

[44]  L. Valentin,et al.  Pattern recognition of pelvic masses by gray‐scale ultrasound imaging: the contribution of Doppler ultrasound , 1999, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[45]  P. Kenemans,et al.  Technical evaluation of three second generation CA 125 assays. , 1994, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

[46]  L. Valentin,et al.  The role of ultrasound in the management of women with acute and chronic pelvic pain. , 2004, Best practice & research. Clinical obstetrics & gynaecology.

[47]  L. Blumenson,et al.  Serum CA-125 measurements > 65 U/mL. Clinical value. , 1997, The Journal of reproductive medicine.

[48]  L. Valentin,et al.  Comparison of ‘pattern recognition’ and logistic regression models for discrimination between benign and malignant pelvic masses: a prospective cross validation , 2001, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.